Onswik (insulin efsitora alfa) is a long-acting insulin therapy indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Administered as a once-weekly subcutaneous injection, Onswik is designed to provide basal insulin activity over an extended dosing interval. Like other insulin therapies, it helps lower blood glucose by promoting glucose uptake into cells and reducing glucose production by the liver.
Onswik offers a less frequent dosing option for basal insulin therapy, potentially simplifying treatment for appropriate patients with type 2 diabetes. Clinical studies have evaluated its ability to provide glycemic control comparable to daily basal insulin therapies. Its once-weekly administration represents a differentiated approach to insulin treatment and may support treatment convenience and adherence.
